Clonal Versus Nonclonal ET: Some Remaining Questions
| 1. Can nonclonal ET progress to clonal disease? |
| 2. What is the incidence of megakaryocyte restricted clonality? |
| 3. How common are mutations in the TPO gene? |
| 4. Are patients with clonal disease the only ones at risk for transformation to AML? |
| 5. Does the incidence of thrombotic complications vary depending on clonality? |
| 6. Should clonality affect the choice of cytoreductive therapy? |
| 7. When will we be able to routinely distinguish thrombocythemia vera from secondary thrombocythemia? |
| 1. Can nonclonal ET progress to clonal disease? |
| 2. What is the incidence of megakaryocyte restricted clonality? |
| 3. How common are mutations in the TPO gene? |
| 4. Are patients with clonal disease the only ones at risk for transformation to AML? |
| 5. Does the incidence of thrombotic complications vary depending on clonality? |
| 6. Should clonality affect the choice of cytoreductive therapy? |
| 7. When will we be able to routinely distinguish thrombocythemia vera from secondary thrombocythemia? |